The elucidation of the E2F1-ASH1L-AS1/APPLE-ERK1/2 signaling axis not only advances our understanding of MAPK regulation in liver cancer but also identifies a promising target for precision therapy with significant translational potential. This evidence concerns the gene MAPK3 and liver cancer.